WHO ICTRP trial
A Phase 3 Study of Atezolizumab in Patients With Non-Small Cell Lung Cancer
JPRN-jRCT2080222480 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080222480 |
|---|---|
| Public title | A Phase 3 Study of Atezolizumab in Patients With Non-Small Cell Lung Cancer |
| Scientific title | A Randomized Phase 3 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy |
| Primary sponsor | Chugai Pharmaceutical Co., Ltd. |
| Secondary sponsors | F. Hoffmann-La Roche Ltd |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Asia except Japan;North America;South America;Europe;Japan;Oceania |
| Conditions | Non-Small Cell Lung Cancer |
| Interventions | investigational material(s) Generic name etc : Atezolizumab INN of investigational material : atezolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 1200 mg intravenous… |
| Registration date | Jul 5, 2014 |
| Target size | 1100 |
| Secondary IDs | NCT02008227;JapicCTI-142530 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: